Literature DB >> 19879251

Development of tolerance in D3 dopamine receptor signaling is accompanied by distinct changes in receptor conformation.

Ligia Westrich1, Sara Gil-Mast, Sandhya Kortagere, Eldo V Kuzhikandathil.   

Abstract

The D3 but not D2 dopamine receptors exhibit a tolerance property in which agonist-induced D3 receptor response progressively decreases upon repeated agonist stimulation. We have previously shown that the D3 receptor tolerance property is not mediated by receptor internalization, persistent agonist binding or a decrease in receptor binding affinity. In this paper, we test the hypothesis that alterations in D3 receptor conformation underlie the tolerance property. Structural models of wild type and mutant human D3 receptors were generated using the beta adrenergic receptor crystal structure as a template. These models suggested that the agonist-bound D3 receptor undergoes conformational changes that could underlie its tolerance property. To experimentally assess changes in receptor conformation, we measured the accessibility of native cysteine residues present in the extracellular and transmembrane regions of the human D3 receptor to two different thiol-modifying biotinylating reagents. The accessibilities of the native cysteine residues present in the D3 receptor were assessed under control conditions, in the presence of agonist and under conditions that induced receptor tolerance. By comparing the accessibility of D3 receptor cysteine residues to hydrophobic and hydrophilic thiol-modifying biotinylating reagents, we show that the alteration of D3 receptor conformation during tolerance involves the net movement of cysteine residues into a hydrophobic environment. Our results show that the conformation state of the D3 receptor during tolerance is distinct from the conformation under basal and agonist-bound conditions. The results suggest that the D3 receptor tolerance property is mediated by conformational changes that may uncouple the receptor from G-protein signaling. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879251     DOI: 10.1016/j.bcp.2009.10.016

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors.

Authors:  C Min; M Zheng; X Zhang; M G Caron; K M Kim
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  Identification and characterization of a novel class of atypical dopamine receptor agonists.

Authors:  E V Kuzhikandathil; S Kortagere
Journal:  Pharm Res       Date:  2012-05-01       Impact factor: 4.200

3.  Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.

Authors:  Wei Xu; Xiaozhao Wang; Aaron M Tocker; Peng Huang; Maarten E A Reith; Lee-Yuan Liu-Chen; Amos B Smith; Sandhya Kortagere
Journal:  ACS Chem Neurosci       Date:  2016-11-23       Impact factor: 4.418

4.  An amino acid residue in the second extracellular loop determines the agonist-dependent tolerance property of the human D3 dopamine receptor.

Authors:  Sara Gil-Mast; Sandhya Kortagere; Kokila Kota; Eldo V Kuzhikandathil
Journal:  ACS Chem Neurosci       Date:  2013-03-21       Impact factor: 4.418

5.  Opposing aging-related shift of excitatory dopamine D1 and inhibitory D3 receptor protein expression in striatum and spinal cord.

Authors:  Benjamin E Keeler; Perrine Lallemand; Mukund M Patel; Lisandra E de Castro Brás; Stefan Clemens
Journal:  J Neurophysiol       Date:  2015-11-11       Impact factor: 2.714

Review 6.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

Review 7.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01

Review 8.  Abnormalities of Dopamine D3 Receptor Signaling in the Diseased Brain.

Authors:  G Aleph Prieto
Journal:  J Cent Nerv Syst Dis       Date:  2017-08-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.